文献速递皮肤肿瘤

微小RNA-211缺失促进黑色素瘤代谢脆弱性并增加BRAF抑制剂敏感性

MicroRNA-211 Loss Promotes Metabolic Vulnerability and BRAF Inhibitor Sensitivity in Melanoma.
PubMed 文献 · J Invest Dermatol · 2018-08-01

研究用CRISPR/Cas9构建miR-211缺失黑色素瘤细胞系,发现其缺失可减慢体外生长与侵袭、抑制磷脂酰肌醇-3-激酶信号及体内肿瘤生长,并削弱线粒体呼吸和三羧酸循环;miR-211可被维莫非尼上调,在维莫非尼耐药细胞中高表达,缺失后细胞对药物更敏感。

要点

  • miR-211缺失减慢黑色素瘤细胞体外生长与侵袭,并抑制体内肿瘤生长。
  • miR-211缺失削弱线粒体呼吸和三羧酸循环,使细胞代谢脆弱。
  • 维莫非尼上调miR-211,耐药细胞中miR-211升高,其缺失使细胞对维莫非尼更敏感。

核心结论

  • miR-211缺失通过抑制促生长信号通路和使细胞代谢脆弱双重机制发挥抗癌作用,作者认为其是黑色素瘤极具吸引力的特异性候选联合治疗靶点。

研究设计与样本

  • 研究利用CRISPR/Cas9技术构建miR-211功能缺失细胞系,进行体外和体内实验。

主要发现

  • miR-211缺失减慢体外生长和侵袭,抑制磷脂酰肌醇-3-激酶信号,并抑制体内黑色素瘤生长。
  • miR-211缺失减弱线粒体呼吸和三羧酸循环,使黑色素瘤细胞代谢脆弱。
  • miR-211被BRAF抑制剂维莫非尼上调,在维莫非尼耐药黑色素瘤细胞中表达升高,miR-211缺失使这些细胞对维莫非尼更敏感。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical management of malignant melanoma remains a challenge because these tumors are intrinsically aggressive and prone to therapeutic resistance. MicroRNA (miR)-211 is an emerging melanoma oncogene. Melanoma metabolism adapts to promote survival, including in response to BRAFV600E inhibition, but how miR-211 participates in this process is unknown. Here, we generated miR-211 loss-of-function cell lines using CRISPR/Cas9 technology and show that miR-211 loss slowed growth and invasion in vitro, inhibited phosphoinositol-3-kinase signaling, and inhibited melanoma growth in vivo. miR-211 deficiency rendered melanoma cells metabolically vulnerable by attenuating mitochondrial respiration and tricarboxylic acid cycling. miR-211 was up-regulated by the BRAF inhibitor vemurafenib and in vemurafenib-resistant melanoma cells, with miR-211 loss rendering them more drug sensitive. miR-211 loss represents a "two-pronged" anticancer strategy by inhibiting both critical growth-promoting cell signaling pathways and rendering cells metabolically vulnerable, making it an extremely attractive and specific candidate combinatorial therapeutic target in melanoma.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Sahoo A, Sahoo SK, Joshi P, et al. MicroRNA-211 Loss Promotes Metabolic Vulnerability and BRAF Inhibitor Sensitivity in Melanoma. J Invest Dermatol. 2018. PMID: 30076926. doi:10.1016/j.jid.2018.06.189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。